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Abstract: During the last decade, isolation of circulating tumour cells via blood liquid biopsy of
prostate cancer (PCa) has attracted significant attention as an alternative, or substitute, to conventional
diagnostic tests. However, it was previously determined that localised forms of PCa shed a small
number of cancer cells into the bloodstream, and a large volume of blood is required just for a
single test, which is impractical. To address this issue, urine has been used as an alternative to
blood for liquid biopsy as a truly non-invasive, patient-friendly test. To this end, we developed
a spiral microfluidic chip capable of isolating PCa cells from the urine of PCa patients. Potential
clinical utility of the chip was demonstrated using anti-Glypican-1 (GPC-1) antibody as a model of
the primary antibody in immunofluorescent assay for identification and detection of the collected
tumour cells. The microchannel device was first evaluated using DU-145 cells in a diluted Dulbecco’s
phosphate-buffered saline sample, where it demonstrated >85 (±6) % efficiency. The microchannel
proved to be functional in at least 79% of cases for capturing GPC1+ putative tumour cells from the
urine of patients with localised PCa. More importantly, a correlation was found between the amount of
the captured GPC1+ cells and crucial diagnostic and prognostic parameter of localised PCa—Gleason
score. Thus, the technique demonstrated promise for further assessment of its diagnostic value in
PCa detection, diagnosis, and prognosis.
Keywords: prostate cancer; inertial microfluidics; cell separation; tumour cells; glycoprotein
1. Introduction
According to GLOBOCAN 2018, prostate cancer (PCa) is the second most frequent cancer as well
as the second leading cause of the cancer deaths in males worldwide [1]. Statistical reports show that
only a minor decrease in cancer-related mortality has been achieved during the past decade. This was
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primarily due to a lack of efficient techniques for detection and prognosis of PCa, as well as monitoring
the treatment outcomes [2].
Currently, the gold standard for PCa detection is a costly multistage process, which conventionally
includes the prostate-specific antigen (PSA) blood test and subsequent tissue biopsy. However, these
diagnostic techniques have significant limitations. For instance, the PSA test is sensitive to diverse
disorders, including benign prostatic hyperplasia and prostatitis; therefore, its specificity is relatively
low [3]. On the other hand, the tissue biopsy is a highly specific yet invasive examination with possible
adverse side effects as local bleeding and infectious complications including drug resistant bacterial
strains. These shortcomings call for development of cost-effective and reliable alternatives to the
existing diagnostic tests for PCa, which would first of all reduce the number of unnecessary tissue
biopsies. Liquid biopsy via isolation of circulating tumour cells (CTCs) is a promising diagnostic tool
capable of supplementing state-of-the-art PCa diagnostics [4]. However, standard liquid biopsy of the
blood samples from PCa patients suffers from low CTC yield, especially in the case of the localised
forms of cancer, implying a requirement for providing a large volume of blood for PCa detection.
This requirement makes the feasibility of the standard liquid biopsy questionable. Urine represents
an obvious and natural choice of the biological fluid to yield diagnostically relevant amounts of
cancer cells from patients with diverse urologic cancers including PCa [5,6]. Since a prostate gland is
anatomically connected to the lower part of the urinary tract in males, diverse cells can be shed from
the gland into the urinary tract, including tumour cells, which can be concomitantly washed out in
the process of urination. The major advantages of the tumour cell isolation via liquid biopsy of the
urine in comparison with the isolation of CTCs from the blood, as a truly non-invasive method, is a
lack of limitation in the sample volume. Compared with blood, urine can be readily collected, stored,
and transported. The urine collection process has enviable patient compliance and does not require a
skilled medical professional.
Recently, isolation of tumour cells from biological samples via microfluidic technology has gained
significant attention. Among the existing microfluidic modalities, inertial microfluidics based on a
spiral microchannel device configuration has experienced a massive growth as exemplified by the
separation of CTCs and circulating fetal trophoblasts [7–10], identification of bacterial spoilage from
beers [11], blood fractionation [12], enrichment of circulating head and neck tumour cells [13], and
separation of microalgae [14]. The technique is attractive for its cost-effectiveness and high throughput.
The technology exploits inertial lift and Dean drag forces exerted on cells and particles flowing through
the spiral microchannel. The interplay of these two forces causes lateral migration of cells and their
focussing at equilibrium positions. As the amount of these two forces is directly related to the cell size,
the cell eventually equilibrates at a lateral position, which precisely corresponds to its diameter. As a
result, the larger cells (or particles, or both) tend to focus at regions near the inner wall, whereas the
smaller cells (or particles, or both) tend to move away from it.
In this communication, we report on the development of a microfluidic chip capable of collecting
PCa tumour cells from the urine using the principles of cell sorting employing inertial microfluidics.
Isolated tumour cells were assayed via immunocytochemistry with monoclonal mouse anti-glypican-1
(anti-GPC-1) [15] antibody MIL-38 (Minomic International Ltd., Sydney, NSW, Australia) previously
reported to be highly specific and sensitive in the detection of PCa [16]. MIL-38 was used as a model
primary antibody. The GPC-1 is a heparan sulphate proteoglycan which is found attached to the cancer
cell surface and which has recently received significant attention as a biomarker for PCa, especially in
terms of evaluating its aggressiveness and growth [17]. Furthermore, to showcase the versatility of the
developed microchannel in terms of diagnosis and prognosis of localised PCa, correlations between
the number of isolated tumour cells and conventional diagnostic parameters of PCa such as the level
of prostate-specific antigen (PSA) in blood and Gleason score (GS) were analysed.
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2. Methods
2.1. Device Design and Fabrication
A spiral microchannel device for the isolation of PCa cells from urine samples was designed,
fabricated, and tested. This device represented an adaptation of the microfluidic technology previously
developed for the isolation of CTCs from peripheral blood [9,18]. Briefly, polydimethylsiloxane (PDMS)
pre-polymer with the curing agent (Sylgard 184, DowsilCorp., Midland, MI, USA) were first mixed
at the ratio of 10:1 and then was degassed in a vacuum chamber. This mixture was poured onto an
aluminium mold with subsequent baking in a laboratory oven for 2 hours at 70 ◦C. The mold can be
fabricated via a milling process [19] or 3D printing technology [20]; in this study, we used a milling
process. Furthermore, the cured PDMS was peeled from the mold, and holes with 1.5 mm diameter
were pierced with a Uni-Core™ Puncher (Sigma-Aldrich Co. LLC., Singapore) at the sites designated
for the inlet and outlets of the chip. Eventually, the PDMS microchannel was irreversibly bonded to
another layer of PDMS using an oxygen plasma machine (Harrick Plasma, Ithaca, NY, USA).
2.2. Experimental Setup and Procedure
The efficiency of the spiral microfluidic chip for capturing PCa tumour cells was evaluated by
spiking a predetermined number of DU-145 cells (ATCC HTB-81) (approximately 1000) into 50 mL of
Dulbecco’s phosphate-buffered saline (DPBS). The solution was injected into the chip using a peristaltic
pump (Baoding Shenchen Precision Pump Co., Ltd, Baoding, China) at a 1.7-mL/min flow rate. When
the volume of DPBS in the sample tube decreased to 1 mL, enriched cells were deposited onto an
adhesive glass slide (ThermoFisher Scientific, Scoresby, VIC, Australia) using a Thermo Scientific™
Cytospin™ 4 Cytocentrifuge (ThermoFisher Scientific, Scoresby, VIC, Australia) and then air-dried.
To determine if there were cells in the waste outlet, DPBS in the waste tube was centrifuged, and
cell pellets were deposited onto 4 adhesive glass slides with Cytospin™ 4 Cytocentrifuge for further
quantitation. Deposited cells on slides were fixed with ice-cold acetone for 3 min at –20 ◦C and
mounted with a Fluoroshield medium containing 4′,6-diamidino-2-phenylindole (DAPI) Prolong Gold
Antifade Reagent(ThermoFisher Scientific, sScoresby, VIC, Australia) covered with a coverslip and
counted using a fluorescence microscope (Zeiss Axio Imager Z2 Upright Microscope, North Ryde,
NSW, Australia).
2.3. Ethics Statement and Clinical Sample Preparation
A part of this study that includes collection and analysis of clinical samples from patients with
localised PCa was conducted under an ethical approval provided by Macquarie University Human
Research Ethics Committee (HREC No: 5201500707), Australia. All patients and healthy volunteers
provided written informed consent for collection of the samples and provision of their clinical data.
The samples were collected and analysed in a non-blinded manner, 14 midstream urine samples from
healthy volunteers and fourteen midstream urine samples from patients with localised PCa were
acquired. The midstream specimen of urine was chosen for analysis to avoid possible channel occlusion
with debris which may present in the first pass specimen. The volume of urine collected from patients
and healthy volunteers varied from 30 to 100 mL. Prior to sample processing, the amount of cells per
mL of urine was identified with an automated cell counter (TC20™ Automated Cell Counter, Bio-Rad,
Gladesville, NSW, Australia). After the sample collection, samples were processed through the spiral
microchannel on the same day with the peristaltic pump at the optimum flow rate of 1.7 mL/min.
During the sample processing, once the volume reduced to approximately 5 mL, 5 mL of DPBS was
added, and the processing was continued until the volume of solution decreased to approximately
1 mL. Afterwards, cells from the solution were sedimented with Cytospin™ 4 Cytocentrifuge onto four
adhesive glass slides. The glass slides were then air-dried and fixed with ice-cold acetone for 3 min at
–20 ◦C and processed either immediately or stored at 4 ◦C in a dry chamber and analysed within a
week. The schematic representation of the sample processing is illustrated in Figure 1.




Figure 1. A schematic representation of the workflow for PCa cell detection from the urine sample 
employing a spiral microfluidic chip. First, PCa cells shed from the prostate gland into the urethra are 
collected into a container in the process of urination. Then, the collected PCa cells present in urine are 
isolated via processing through the spiral microchannel. Finally, the collected cells are labelled with 
fluorescent antibodies, i.e., anti-GPC-1 and immunoassayed under a microscope. 
2.4. Immunofluorescence Staining 
All incubations were performed in a humidified chamber. Cells were fixed on the surface of dry 
glass slides, rehydrated in DPBS for 3 min, followed by blocking with 1% Bovine Serum Albumin 
(BSA) solution in DPBS for 1 h at room temperature. Cells were then incubated for 2 h at room 
temperature with an MIL-38 anti-GPC-1 mouse primary antibody diluted in blocking solution (1% 
BSA) at 10 μg/mL. At this step, one of the 4 slides was incubated with the blocking agent instead of 
the secondary antibody and was used as a secondary antibody alone control to monitor the non-
specific binding of second antibody. Then, the glass slides were washed with DPBS 3 times for 5 min 
and air-dried. Then, cells were incubated for 1 h with goat-anti-mouse Alexa Fluor 488 (Abcam, 
Australia) diluted in the blocking solution at 4 μg/mL and washed with DPBS 3 times for 5 min after 
the incubation. Finally, cells were mounted with a Fluoroshield medium containing DAPI, covered 
with a coverslip, and observed under a fluorescence microscope. 
2.5. Cell Enumeration and Data Analysis 
To identify a quantitative gold standard for enumeration of GPC-1+ putative tumour cells 
collected from the urine samples, approximately DU-145 cells were added to a healthy urine sample, 
processed with the chip, immunostained as described above, captured under the fluorescence 
microscope, and the intensity of fluorescence signal from the cells was measured with ImageJ 
software. Then, a mean (±SD) for the signal intensity was calculated, and the intensity at the value 
equal to mean–SD was chosen as the threshold. Above this threshold, cells from the urine samples of 
PCa patients or healthy volunteers were registered as putative tumour cells and counted. Thus, in 
the case of cells isolated from the urine sample of PCa patients, during observation under the 
microscope, images of suspicious cells were captured, and the cells were analysed with ImageJ 
software for signal intensity. GPC-1+ cells whose signal intensity was higher than the mean–SD 
(determined using DU-145 cells) were registered as putative tumour cells and counted. Finally, to 
evaluate potential diagnostic and prognostic value of the technique, correlations between the amount 
of GPC-1+ cells collected from the patients and the levels of conventional PCa markers such as the 
blood PSA level and GS were measured. To further evaluate the applicability of the developed 
microfluidic device, correlations between the amount of collected GPC-1+ cells, the volume of the 
Figure 1. A schematic representation of the workflow for PCa cell detection from the urine sample
employing a spiral microfluidic chip. First, PCa cells shed from the prostate gland into the urethra are
collected into a container in the process of urination. Then, the collected PCa cells present in urine are
isolated via processing through the spiral microchannel. Finally, the collected cells are labelled with
fluorescent antibodies, i.e., anti-GPC-1 and immunoassayed under a microscope.
2.4. Immunofluorescence Staining
All incubations were performed in a humidified chamber. Cells were fixed on the surface of dry
glass slides, rehydrated in DPBS for 3 min, followed by blocking with 1% Bovine Serum Albumin (BSA)
solution in DPBS for 1 h at room temperature. Cells were then incubated for 2 h at room temperature
with an MIL-38 anti-GPC-1 mouse primary antibody diluted in blocking solution (1% BSA) at 10 µg/mL.
At this step, one of the 4 slides was incubated with the blocking agent instead of the secondary antibody
and was used as a secondary antibody alone control to monitor the non-specific binding of second
antibody. Then, the glass slides were washed with DPBS 3 times for 5 min and air-dried. Then, cells
were incubated for 1 h with goat-anti-mouse Alexa Fluor 488 (Abcam, Australia) diluted in the blocking
solution at 4 µg/mL and washed with DPBS 3 times for 5 min after the incubation. Finally, cells were
mounted with a Fluoroshield medium containing DAPI, covered with a coverslip, and observed under
a fluorescence microscope.
2.5. Cell Enumeration and Data Analysis
To identify a quantitative gold standard for enumeration of GPC-1+ putative tumour cells collected
from the urine samples, approximately DU-145 cells were added to a healthy urine sample, processed
with the chip, immunostained as described above, captured under the fluorescence microscope, and the
intensity of fluorescence signal from the cells was measured with ImageJ software. Then, a mean (±SD)
for the signal intensity was calculated, and the inte sity at the value equal to mean–SD as chosen as
the threshold. Above this threshold, cells from the urine samples of PCa patients or healthy volunteers
were registered as putative tumour cells and counted. Thus, in t e case of cells isolated from the urine
sample of PCa patients, during observation under the microscope, images of suspicious cells were
captured, and the cells were analysed with I ageJ software for signal intensity. GPC-1+ cells whose
signal intensity was higher than the mean–SD (determine using DU-145 cells) were registered as
putative tumour cells and counted. Finally, to evaluate pote tial diagnostic and prognostic value of the
technique, correlations between the amount of GPC-1+ cells collected from the patients and the levels
of conventional PCa markers such as the blood PSA level and GS were measured. To further evaluate
the applicability of the developed microfluidic device, correlations between the amount of collected
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GPC-1+ cells, the volume of the urine sample and total amount of cells in urine sample (mL−1) were
measured. The correlations were calculated using Microsoft Excel 2016 software (Microsoft, Redmond,
WA, USA).
3. Results
3.1. Spiral Microfluidic Device
In this study, we report a novel, efficient, and non-invasive method for isolation of tumour cells
from urine samples. This is the first time, to the best of our knowledge, that detection of PCa cells
using the urine samples based on inertial microfluidics in a spiral channel has been reported.
Prostate cancer cells experience two major inertial lift and Dean drag forces inside the spiral







Fd = 5.4× 10−4πµDe1.63a , (2)
where Umax indicates the maximum fluid velocity, ρ is the fluid density, µ denotes the dynamic viscosity
of the fluid, CL is the lift force coefficient, Dh represents the channel hydraulic diameter, a is the
particle diameter, and De is Dean number. Considering these equations, a particle (or cell) of the
diameter a experiences FL and Fd different uniquely determined by the a [11]. As schematically shown
in Figure 1, the larger cells (prostate cancer cells) are focussed at the inner wall (where its height is
purpose-designed to be smaller than that of the outer wall), whereas the smaller cells and debris drift
to the outer wall.
Generally, the ratio of particle diameter to the height of channel, as well as the hydraulic diameter
of microchannel play a critical role in the particle focussing. The channel cross-section designed in this
study was carefully analysed to focus PCa cells (~15–20 µm) featuring a trapezoidal cross-section with
the base of 600 µm, inner wall of 90 µm, and outer wall of 140 µm. The bifurcation at the outlet of the
channel was placed at a location 350 µm to the inner wall. Upon the optimisation of the channel flow
rate, DU-145 cells in DPBS solution were introduced from the inlet via a peristaltic pump. The results
demonstrated that the flow rate of 1.7 mL/min was optimal where 85 (±6) % of cells were collected
through the target outlet (Figure 2).
3.2. Collection of GPC-1+ cells from Urine
Midstream urine samples in volumes ranging from 30 to 100 mL were collected from 14 patients
with localised PCa and processed using our spiral microfluidic chip. GPC-1+ cells exhibiting the
fluorescence signal >1781 arbitrary units, according to the mean (2069)-SD (288) arbitrary units
measured from DU-145 cells with ImageJ were registered as putative tumour cells. Mostly, these cells
exhibited round nuclei and a high ratio of nuclear to cytoplasmic size. We note that these cells were
located in groups or clusters (Figure 3A,B). Putative tumour cells were detected in 12 out of 14 patients
(86%). The total amount of detected cells (n) varied from 4 to 194 among the samples and patients, with
the median value of 22. In the case of healthy volunteers, 11 samples out of 14 (79%) were negative in
terms of GPC-1+ cells. It is worthy to note that the urine samples of the 3 healthy volunteers registered
as GPC-1+ positive, contained only <8 cells. Thus, in case of PCa patients, only those patients whose
urine samples contained n > 8 were considered positive with confidence. Accordingly, the number of
such positive patients was 11 out of 14 (79%) (Table 1).




Figure 2. (A) schematic representation of the processing of a urine sample containing PCa cells 
through the spiral microfluidic chip. Samples are introduced via a peristaltic pump and then recycled 
until 1 mL of the urine sample remains in the sample tube. Then, PCa assaying is implemented by the 
use of fluorescent antibodies; (B) illustration of the bifurcation of the spiral, target (sample), and waste 
outlets. The results show that most of cells were collected through the target outlet. The flow rate of 
1.7 mL/min was selected as the optimum flow rate for the separation efficiency of PCa cells; (C) 85 
(±6) % of cells were collected through the sample outlet of the chip; (D) experimental setup used in 
this study; (E) state of urine sample before processing, and (F) after processing, when about 1 mL of 
sample remains in the tube. The remaining 1-mL contains most of PCa cells and is subsequently 
analysed as described. 
3.2. Collection of GPC-1+ cells from Urine 
Midstream urine samples in volumes ranging from 30 to 100 mL were collected from 14 patients 
with localised PCa and processed using our spiral microfluidic chip. GPC-1+ cells exhibiting the 
fluorescence signal >1781 arbitrary units, according to the mean (2069)-SD (288) arbitrary units 
measured from DU-145 cells with ImageJ were registered as putative tumour cells. Mostly, these cells 
exhibited round nuclei and a high ratio of nuclear to cytoplasmic size. We note that these cells were 
located in groups or clusters (Figure 3A and B). Putative tumour cells were detected in 12 out of 14 
patients (86%). The total amount of detected cells (𝑛) varied from 4 to 194 among the samples and 
Figure 2. (A) schematic repr sentation f the processing of a urine sample containing PCa cells through
the spiral microfluidic chip. Samples are introduced via a perist ltic pump and the recycled until
1 mL of the urine sample remains in the sample tube. Then, PCa assaying is implemented by the use of
fl orescent antibodies; (B) illustrat on of the bifurcation of the spiral, target (sample), nd waste outlets.
The r sults show that m st of cells were o ected thr ugh the target outl t. Th flow rate of 1.7 mL/min
was selected as the optimum flow rate for the sep rati n effici ncy of PCa cells; (C) 85 (±6) % of cells
were collect d through th sample tlet of the chip; (D) xperimental setup used n this study; (E) state
of urine sample before processing, and (F) afte processing, when about 1 mL of sample remains in the
tube. The remaining 1-mL contains most of PCa cells and is subsequently naly ed as de crib d.
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patients, with the median value of 22. In the case of healthy volunteers, 11 samples out of 14 (79%) 
were negative in terms of GPC-1+ cells. It is worthy to note that the urine samples of the 3 healthy 
volunteers registered as GPC-1+ positive, contained only <8 cells. Thus, in case of PCa patients, only 
those patients whose urine samples contained 𝑛  > 8 were considered positive with confidence. 
Accordingly, the number of such positive patients was 11 out of 14 (79%) (Table 1).  
Table 1 The number of glypican-1+ (GPC-1)+ cells detected in the urine samples and relevant clinical 
diagnostic test results. The number of cells with high GPC-1+ expression (𝑛) isolated from the patients’ 
and urine samples varied from 4 to 194 units with the median value of 22. 𝑛 was <8 in the urine 
samples of the healthy volunteers, i.e., 11 (79%) out of 14 healthy volunteers were registered PCa-
negative in terms of the 𝑛-number. The number of patients positive with confidence for GPC-1+ cells 











1 23 90 1.6 × 104 5.4 6 
2 21 30 8.1 × 103 8.7 7 
3 37 100 1.3 × 104 7 8 
4 16 60 6.3 × 104 4.4 6 
5 4 60 4.4 × 103 11 8 
6 10 40 5.2 × 104 4.9 7 
7 37 30 1.5 × 104 7.2 7 
8 12 90 8.3 × 104 3.9 7 
9 194 40 3.6 × 104 7.9 8 
10 42 50 7.4 × 104 11.6 6 
11 0 40 1.9 × 104 1.3 6 
12 37 30 9.7 × 103 11 7 
13 11 50 1.5 × 104 5.5 6 
14 0 70 2.7 × 103 5.6 6 
n—number of GPC1+ cells; N—total number of cells in the analysed sample. 
Low negative correlation between the amount of GPC-1+ cells and the volume of urine sample 
(r = -0.18, where r is correlation coefficient) and negligible positive correlation between the amount 
of GPC-1+ cells and the total number of cells per mL of the initial urine sample (r = 0.02) were 
identified. At the same time, moderate positive correlation between the volume of the urine sample 
and the total number of cells (mL-1) (r = 0.32) was identified. Among all 28 samples analysed, 1 (4%) 
sample was discarded due to the high concentration of non-cellular elements (i.e., urine crystals). 
 
Figure 3. Numerous glypican-1+ (GPC-1+) cells (A), two GPC-1+ cells and one GPC-1− squamous 
epithelial cell (B) isolated from the samples of PCa patients. The GPC-1+ putative tumour cells 
typically featured a high ratio of the nucleus to cytoplasm size and were prone to grouping or 
clustering.  
Figure 3. Numerous glypican-1+ (GPC-1+) cells ( ), two GPC-1+ cells and one GPC-1− squamous
epithelial cell (B) isolated from the samples of PCa patients. The GPC-1+ putative t mour cells typically
featured a high ratio of the nucleus to cytoplasm size and were prone to grouping or clustering.
Table 1. The number of glypican-1+ (GPC-1)+ cells detected in the urine samples and relevant clinical
diagnostic test results. The number of cells with high GPC-1+ expression (n ) isolated from the patients’
and urine samples varied from 4 to 194 units with the median value of 22. n was <8 in the urine samples
of the healthy volunteers, i.e., 11 (79%) out of 14 healthy volunteers were registered PCa-negative in
terms of the n -number. The number of patients positive with confidence for GPC-1+ cells (n > 8) was






level (ng/mL) Total GS
1 23 90 1.6 × 104 5.4 6
2 21 30 8.1 × 103 8.7 7
3 37 100 1.3 × 104 7 8
4 16 60 6.3 × 104 4.4 6
5 4 60 4.4 × 103 11 8
6 10 40 5.2 × 104 4.9 7
7 37 30 1.5 × 104 7.2 7
8 12 90 8.3 × 104 3.9 7
9 194 40 3.6 × 104 7.9 8
10 42 50 7.4 × 104 11.6 6
11 0 40 1.9 × 104 1.3 6
12 37 30 9.7 × 103 11 7
13 11 50 1.5 × 104 5.5 6
14 0 70 2.7 × 103 5.6 6
n—number of GPC1+ cells; N—total number of cells in the analysed sample.
Low negative correlation between the amount of GPC-1+ cells and the volume of urine sample
(r = −0.18, where r is correlation coefficient) and negligible positive correlation between the amount of
GPC-1+ cells and the total number of cells per mL of the initial urine sample (r = 0.02) were identified.
At the same time, moderate positive correlation between the volume of the urine sample and the total
number of cells (mL−1) (r = 0.32) was identified. Among all 28 samples analysed, 1 (4%) sample was
discarded due to the high concentration of non-cellular elements (i.e., urine crystals).
3.3. Analysis of Potential Diagnostic Applicability of the Method
To evaluate the flexibility of the method proposed in this study for early detection and diagnosis
of PCa, correlations between the amount of isolated putative tumour cells and conventional diagnostic
parameters of PCa were analysed. Thus, correlations between the amount of GPC-1+ cells (n) and
PSA level, or total GS were recognised (Figure 4). Furthermore, correlations between the ratio of
n/V (where V is volume of urine sample), or the ratio n/N (where N is a total number of cells in
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urine sample), and PSA level, or GS, were also identified. As a result, low positive correlations were
identified between n and PSA level (r = 0.27) as well as n/V and PSA level (r = 0.30), moderately
positive correlations between n and GS (r = 0.48), and between n/V and GS (r = 0.46), and moderately
positive correlations between n/N and PSA level (r = 0.47) and GS (r = 0.61).
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Figure 4. Correlations between the amount of GPC1+ cells (𝑛), 𝑛/𝑉 (𝑉, volume of urine sample), 𝑛/𝑁 
(𝑁, total number of cells in urine sample) and conventional clinicopathological parameters of the PCa–
prostate specific antigen (PSA) level and Gleason score (GS). The lowest correlation was identified 
between 𝑛 and PSA level, and the highest correlation was identified between 𝑛/𝑁 and GS. 
4. Discussion 
PSA screening is the most common method of early detection of PCa. A prostate biopsy remains 
the only definitive diagnostic test for the presence of PCa. However, the high prevalence of false 
Figure 4. Correlations between the amount of GPC1+ cells (n), n/V (V, volume of urine sample),
n/N (N, total number of cells in urine sample) and conventional clinicopathological parameters of the
PCa–prostate specific antigen (PSA) level and Gleason score (GS). The lowest correlation was identified
between n and PSA level, and the highest correlation was identified between n/N and GS.
4. Discussion
PSA screening is the most common method of early detection of PCa. A prostate biopsy remains
the only definitive diagnostic test for the presence of PCa. However, the high prevalence f false positive
PSA tests gives rise to a large number of un-necessary prostate biopsies. There remains a high clinical
need for tests better able to guide a decision to proceed to prostate biopsy. This provides an opportunity
to choose the right time for surgical intervention in the case of the parameter increments [21]. However,
the specificity of PSA screening is not high and a GS is obtained via an invasive tissue biopsy causing
significant discomfort to a patient. In recent years, early diagnosis and prognosis of PCa by means of
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CTC isolation via liquid biopsy of blood has been broadly investigated. However, progress has been
minimal and the technique is not efficient due to the low number of CTCs in a standard sample of
7.5 mL of peripheral blood [22]. As an alternative, in this study, we developed and investigated a
high-throughput microfluidic chip for enrichment of PCa tumour cells derived from the urine.
In the pilot enrichment of DU-145 cells from DPBS, the chip demonstrated 85 (±6)% efficiency in
capturing cells at the optimum flow rate i.e., 1.7 mL/min. For urine sample analysis, 12 out of 14 PCa
patient samples (86%) were positive, and 11 out of 14 patients (79%) were positive with confidence in
terms of cells with the high level of GPC-1+ expression—the cells which were registered as putative
tumour cells in the current study. At the same time, 11 out of 14 healthy volunteers (78%) were
identified as PCa-negative in terms of GPC-1+ cells. Such results corresponded to the specificity and
sensitivity of anti-GPC1 primary antibody MIL-38 used as a model primary antibody for the detection
of putative tumour cells [16]. A median amount of GPC-1+ cells of 22 units, captured from patient
samples, identifies urine as a preferable medium for liquid biopsy of localised PCa. Furthermore,
low negative correlation (r = −0.18) identified between the amount of captured GPC-1+ cells (n) and
the volume of the urine (V) suggested that the major amount of n were released in the first stream of
the urine—a reasonable assumption considering the anatomical connection of the prostate gland to
urethra [23]. This assumption is corroborated by moderately positive correlation between the total
number of cells in urine samples (N) and V (r = 0.32) alongside a positive correlation between N and n
(r = 0.02). This seems to indicate that other cells normally present in urine are gradually released
during urination.
The low positive correlation between n/V and PSA level (r = 0.30) suggests that larger volumes
of urine do not contain proportionally greater n, and the first stream of urine is sufficient to collect
the majority of PCa cells. Therefore, it can be concluded that ≤30 mL of the voided urine is likely to
be optimal for rapid isolation of tumour cells using our spiral microfluidic chip. The low positive
correlation between n and PSA level (r = 0.27) can be explained by the relatively low specificity of
the PSA level increment as a marker for the PCa progression and aggressiveness [24]. However, the
moderately high correlation between n/N and PSA level (r = 0.47) is noteworthy. The highest positive
correlation in this study was achieved between n/N and GS (r = 0.61) and can be explained by the
high specificity of GS as a marker of the progression and aggressiveness of localised PCa [25]. This
assumption is corroborated by the moderate correlation between n and GS (r = 0.48) and between n/V
and GS (r = 0.46).
The reported technique lends itself to some straightforward improvements. Fine-tuning of the
chip by including an additional outlet to remove large waste elements will enable handling of a greater
variety of urine samples, including samples containing a large amount of urine crystals, which we had
to discard. The use of more specific and sensitive PCa antibodies or their combination will improve the
immunocytochemistry assaying and increase the sensitivity and specificity of our technique.
5. Conclusions
For the first time, to the best of our knowledge, we introduce here a spiral microfluidic chip
capable of rapid and label-free isolation of tumour cells from urine. The spiral microchannel used in
this study had a trapezoidal cross-section with a width of 600 µm, an inner wall of 90 µm, and outer
wall of 140 µm. The microchannel was first tested using a spiked cancer cell line, proving its high
efficiency: separation of ca 86% of cancer cells at the optimum flow rate of 1.7 mL/min. Secondly,
≥79% of the analysed clinical samples from urine of patients with localised PCa were positive for
GPC-1+ putative tumour cells. Thirdly, moderate correlations were observed between the ratio of
GPC-1+ cells (n) to the total number of isolated cells (N) and PSA; n and GS; and n/V (V, urine volume)
and GS. These results demonstrate promise of the spiral inertial microfluidic technique in terms of
diagnosis and prognosis of localised PCa by liquid biopsy of urine, paving the way for inexpensive
rapid, non-invasive diagnosis, as well as screening and monitoring therapeutic outcomes of PCa and
other urology cancers.
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